Merit Medical Systems Expands with Strategic Gastroesophageal Acquisition
Company Announcements

Merit Medical Systems Expands with Strategic Gastroesophageal Acquisition

Merit Medical Systems (MMSI) has provided an update.

On July 1, 2024, Merit successfully acquired the EsophyX® Z+ device and related assets from EndoGastric Solutions, Inc. for $105 million, expanding its portfolio into non-pharmacological treatments for gastroesophageal reflux disease. This strategic acquisition, financed through Merit’s long-term credit facility, also included the assumption or reimbursement of certain liabilities and was backed by a buyer-side representation and warranty insurance policy. Following the deal, Merit signed additional agreements ensuring a smooth transition of the business operations and assets.

Learn more about MMSI stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyMerit Medical completes acquisition of Cook Medical’s lead management portfolio
TheFlyMerit Medical price target raised to $109 from $107 at Baird
TipRanks Auto-Generated NewsdeskMerit Medical Reports Strong Q3 2024 Earnings Growth
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App